CAP inhibition facilitates the identification of the primary sensitizing venom in patients with clinically presumed Vespa crabro stings: implications for venom immunotherapy selection
Show more: Authors information and Publication history
Authors Information
1Department of Medicine, University of Udine, Udine, Italy
2Clinical Pathology Institute, Department of Laboratory Medicine, Friuli Centrale University Health Authority, Udine, Italy
3Allergy Unit, Mirano-Dolo, Venice, Italy
4Dermatology Unit, Mirano, Venice, Italy
5Allergy Unit, Department of Medicine, Cà Foncello Hospital, Treviso, Italy
6Allergy Unit, Department of Medicine, dell’Angelo Hospital, Mestre, Venice, Italy
7Department of Internal Medicine – Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
8 Laboratory Immunology and Allergy Unit, Santa Maria degli Angeli Hospital, Pordenone, Italy
History
Published: 10 November 2026
Accepted: 26 October 2026
Received: 25 August 2026
SUMMARY
Background. Venom immunotherapy (VIT) is the only disease-modifying treatment for Hymenoptera venom allergy, and its effectiveness relies on accurate identification of the venom responsible for primary sensitization. In patients with clinically presumed Vespa crabro stings, this is challenging because extensive IgE cross-reactivity among Vespid venoms and limitations of current diagnostic reagents complicate interpretation of routine investigations. In this setting, CAP inhibition may provide complementary functional information to identify the primary sensitizing venom. Methods. We retrospectively evaluated 42 patients with systemic allergic reactions following clinically presumed Vespa crabro stings. The diagnostic work-up included clinical history, skin testing, serum-specific IgE to whole venom extracts, component-resolved diagnostics, and CAP inhibition. CAP inhibition results were integrated with clinical and laboratory findings to identify the primary sensitizing venom and support VIT selection. Results. Routine investigations frequently showed sensitization to multiple Vespid venoms, making identification of the primary sensitizing venom uncertain. Only one patient displayed a predominant Vespa crabro-specific IgE response, confirmed by CAP inhibition. Five additional patients had Vespa crabro-specific IgE levels comparable to those for other Vespids, together with elevated Api m 5-specific IgE, suggesting sensitization profiles influenced by highly cross-reactive homologous allergens. CAP inhibition improved diagnostic confidence by distinguishing primary sensitization (61.9%) from cross-reactive IgE responses and supported identification of the most appropriate venom for VIT. Conclusions. In clinically presumed Vespa crabro stings, the presumed culprit insect does not necessarily correspond to the primary sensitizing venom. Under current diagnostic conditions, CAP inhibition provides complementary functional information that improves identification of the primary sensitizing venom and may support more suitable VIT selection.






